ABSTRACT
Recombinant, glycosylated prourokinase (r-proUK; ABT-187, Prolyse1) is a single-chain uro-
kinase-type plasminogen activator that is purified to homogeneity from the culture medium of
hybridoma cells. Preclinical data from in vitro clot lysis experiments in human plasma and a
canine femoral artery thrombosis model have demonstrated the efficacy of r-proUK as a potent
thrombolytic agent. The lytic activity of r-proUK is significantly enhanced by the concomitant
administration of heparin as adjunctive therapy. Fibrinogen, plasminogen, and a2-antiplasmin levels are unaltered or only minimally so, in the femoral artery occlusion model. Thus, ABT-187
was characterized as a stable, potent, glycosylated r-proUK that can achieve rapid thrombolysis
with only minimal perturbations of the clotting or fibrinolytic systems.
